Back to News
Market Impact: 0.4
GSK's Jideytro & Ris-Rez Show Positive Data In Two Lung Cancer Studies
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
GSK reported positive clinical data for two lung-cancer medicines. Jideytro showed high response rates in previously untreated ROS1-positive non-small cell lung cancer, while Ris-Rez reduced the risk of death, supporting the company’s oncology pipeline and potential future commercial opportunities.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
GSK0.78
More News
- UK Budget Tests Bond Markets as Fed, ECB and Oil Risks Loom
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Microsoft's Big Bets on AI Start to Pay Off